IDXX vs ZTS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

IDXX is the larger of the two ($54.34B market cap): the incumbent the market prices for continued execution (40.85x forward earnings, beta 1.54). ZTS is the smaller challenger ($33.07B), cheaper on forward earnings (12.71x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

IDXX vs ZTS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricIDXXZTSWhat it tells you
Market cap$54.34B$33.07BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E40.8512.71Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E46.4713.84Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Beta1.540.68Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range70% of range20% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book29.0710.04How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: ZTS is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how IDXX and ZTS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. IDXX and ZTS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined IDXX and ZTS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does IDEXX Laboratories, Inc. (IDXX) do?

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Its Companion Animal Group, roughly ~92% of revenue, places in clinic analyzers (Catalyst, ProCyte, SediVue and the newer inVue Dx) into practices and then sells the consumables those instruments burn through, while a global reference laboratory network runs the panels clinics send out. Practice management software and digital imaging (ezyVet, Cornerstone, ImageVue) sit alongside the diagnostics and pull more testing through the same customers. Two smaller segments round out the business: Water, which tests drinking water for coliform bacteria, and Livestock, Poultry and Dairy. The company is headquartered in Westbrook, Maine, employs about ~11,000 people, and sells into more than 175 countries.

Full IDXX guide

What does Zoetis (ZTS) do?

Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). Spun out of Pfizer in 2013, it holds leading positions across dermatology, parasiticides, pain, vaccines, and other categories, with well-known franchises such as Apoquel and Cytopoint for pet itch and allergic skin conditions, the Simparica line of parasiticides, and Librela for osteoarthritis pain in dogs. Companion animal products, driven by the long-run humanization of pets and rising spending on their care, have become the larger and faster-growing part of the business, while livestock provides a more staple, protein-demand-linked base. Zoetis sells through veterinarians in the United States and internationally, invests heavily in research and development to sustain its innovation pipeline, and benefits from patents, brand loyalty, and deep vet relationships. Headquartered in Parsippany, New Jersey, it is widely viewed as a defensive-growth leader on the structural trend of people spending more on animal health, though it faces cyclical pet-visit softness, pricing pressure, and rising competition.

Full ZTS guide

IDXX vs ZTS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • IDXX drivers: The CAG Diagnostics recurring annuity; inVue Dx and the premium installed base.
  • ZTS drivers: Leader in a structurally growing market; Innovation-driven franchises and pipeline.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. For ZTS, zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; analysts expect earnings to fall about 3% this year, with Q3 and Q4 EPS each projected about 11-12% lower than a year earlier.

IDXX or ZTS: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick IDXX if you believe its drivers more; ZTS if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the IDXX and ZTS guides.

IDXX vs ZTS: the full fundamentals

IDXX. At roughly ~$564 a share and a market cap near ~$44.5B, IDEXX trades at about ~40x trailing earnings and ~34x the ~$16.73 analysts expect for 2027, and it pays no dividend. That is still a premium to the broader medical device group, though well below the multiples of 45x and above the stock carried through much of the past five years; the shares are down ~16% in 2026 and sit between a 52 week low of ~$501 and a high of ~$770. The twelve analysts Yahoo Finance tracks carry a mean target near ~$701, though JPMorgan trimmed its target to $750 from $775 on October 16.

ZTS. Zoetis has long been valued as a high-quality, defensive-growth compounder at a premium price-to-earnings multiple, but after the 2026 guidance cuts and a roughly 37% year-to-date decline it traded near 12 times forward earnings as of October 16, 2026, closer to a value multiple than its history. The market is pricing in stalled companion-animal growth, softer Librela demand and trade-down by pet owners, against still-high margins and about $2 billion of annual free cash flow. The 15 covering analysts have a mean target near $93.50, and the November 5, 2026 third-quarter report is the next test of whether the outlook has stabilized.

Headline figures (approximate, October 2026): IDXX shows revenue (ttm) ~$4.55B; Q2 2026 revenue up ~9.7% year over year, cag diagnostics recurring revenue (q2 2026) ~$975M, up ~11%, about ~80% of total revenue, margins (ttm) Gross ~62.5%, operating ~35.0%, net ~25.0%, net income and eps (ttm) ~$1.14B net income, ~$14.07 EPS; Q2 EPS ~$4.27 vs ~$3.93 expected; ZTS shows revenue (ttm) ~$9.5 billion; Q2 2026 roughly flat YoY, q2 2026 revenue / adjusted eps ~$2.47 billion / ~$1.87 (vs ~$1.85 est.), operating / net margin (ttm) ~41% / ~28%, net income (ttm) ~$2.6 billion.

The bottom line: IDXX vs ZTS

IDXX and ZTS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined IDXX and ZTS exposure against your real portfolio. It is not an investment adviser.

Wondering how IDXX or ZTS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about IDEXX Laboratories, Inc.

Ask Walnut's AI anything about IDXX and see how it fits what you own.

FAQ

What is the difference between IDXX and ZTS?

+

IDEXX Laboratories (NASDAQ: IDXX) sells diagnostics to veterinarians. Zoetis (ZTS) is the world's largest animal health company, developing and selling medicines, vaccines, diagnostics, and other products for both companion animals (pets like dogs and cats) and livestock (cattle, swine, poultry, and fish). They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is IDXX or ZTS the better stock?

+

Neither is universally better. IDXX is the larger incumbent; ZTS is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, IDXX or ZTS?

+

On forward P/E (as of November 2026), IDXX trades at 40.85x and ZTS at 12.71x, so ZTS is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both IDXX and ZTS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of IDXX vs ZTS?

+

IDXX: Visit volume is the central risk, because if US clinic traffic keeps eroding and testing per visit stops covering the shortfall, the recurring line decelerates toward mid single digits and a ~34x forward multiple has a long way to fall. Wellness visits, down more than ~3%, sit at the discretionary end of veterinary spending and track consumer pressure and muted puppy adoption directly. Competition is intensifying from Mars owned Antech, which absorbed Heska and can now bundle in clinic analyzers with a national laboratory network the way IDEXX does, and from Zoetis in point of care instruments. Roughly ~23% of revenue is non US, so currency both flattered first half reported growth and now costs an estimated ~$15 million against the full year outlook. Leverage is not the concern, at about ~$1.1 billion of debt against ~$197 million of cash and ~$1.6 billion of EBITDA, but the ~27% drawdown from the 52 week high is a reminder of how fast this multiple reprices when the volume narrative wobbles. ZTS: Zoetis faces near-term pressure from softer veterinary visit volumes and increased price sensitivity among pet owners, which have weighed on its companion-animal business and prompted more than one guidance cut in 2026; analysts expect earnings to fall about 3% this year, with Q3 and Q4 EPS each projected about 11-12% lower than a year earlier. Competition is intensifying, including newer entrants and generics in key dermatology and parasiticide categories, and patent expirations can erode pricing over time. A large share of revenue comes from outside the United States, exposing it to currency swings and international regulatory and pricing risk. Livestock demand is tied to protein consumption, herd sizes, and disease outbreaks. The stock already de-rated sharply in 2026 (down about 45% over one year to October 16), showing how a premium multiple can compress when growth stalls. The balance sheet carries about $9.3 billion of debt against about $1.7 billion of cash. It is a growth-oriented holding, not a deep-value or high-yield income stock.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell IDXX or ZTS; figures are approximate and dated (as of November 2026). Verify current data before investing.